- Home
- ARQT vs CSAN Comparison
ARQT vs CSAN Comparison
Compare ARQT & CSAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARQT | CSAN |
|---|---|---|
| Founded | 2016 | 1936 |
| Country | United States | Brazil |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail-Auto Dealers and Gas Stations |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.0B |
| IPO Year | 2020 | 2008 |
Fundamental Metrics
Financial Performance| Metric | ARQT | CSAN |
|---|---|---|
| Price | $26.54 | $2.40 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 2 |
| Target Price | ★ $34.00 | $4.75 |
| AVG Volume (30 Days) | ★ 1.5M | 1.3M |
| Earning Date | 05-06-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.79 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $376,072,000.00 | N/A |
| Revenue This Year | $34.85 | $321.51 |
| Revenue Next Year | $29.39 | $3.57 |
| P/E Ratio | $853.67 | ★ N/A |
| Revenue Growth | ★ 91.34 | N/A |
| 52 Week Low | $15.10 | $2.41 |
| 52 Week High | $31.77 | $6.01 |
Technical Indicators
Market Signals| Indicator | ARQT | CSAN |
|---|---|---|
| Relative Strength Index (RSI) | 50.17 | 25.77 |
| Support Level | $24.91 | N/A |
| Resistance Level | $28.35 | $3.24 |
| Average True Range (ATR) | 1.30 | 0.13 |
| MACD | -0.15 | -0.07 |
| Stochastic Oscillator | 40.18 | 0.00 |
Price Performance
Historical ComparisonAbout ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
About CSAN Cosan S.A. ADS
Cosan SA engages in several services throughout the energy and logistics sectors. Its reportable segments are Raizen, Compass, Moove, Rumo, and Radar. It generates the majority of its revenue from Raizen which operates in the production, commercialization, origination, and trading of ethanol, bioenergy, resale, and trading of electricity, renewable sources, marketing, origination, and trading of sugar and fuels, and lubricant.